Zoryve launches in the U.S. for treatment of seborrheic dermatitis
Click Here to Manage Email Alerts
Key takeaways:
- Zoryve topical foam 0.3% was approved by the FDA on Dec. 15, 2023, for the treatment of seborrheic dermatitis.
- Zoryve will be available for purchase this week through wholesalers and pharmacies.
Arcutis has officially launched sales for Zoryve topical foam 0.3% in the U.S. for the treatment of seborrheic dermatitis in individuals aged 9 years and older, according to a press release.
Approved by the FDA on Dec. 15, 2023, Zoryve (roflumilast, Arcutis) is a once-daily steroid-free foam and is the first drug approved in this indication with a new mechanism of action in more than 2 decades.
“Despite being a very common condition with significant negative impact on quality of life, seborrheic dermatitis has largely been overlooked by the pharmaceutical industry,” Todd Edwards, chief commercial officer at Arcutis, said in the release. “We are proud to launch our second commercial product in the United States and have it immediately available in pharmacies with strong reimbursement from the major pharmacy benefit managers through our already established contracts.”
Zoryve foam will be available for purchase via wholesaler and pharmacy starting this week, according to the press release. Patients can access their prescription information through the Zoryve Direct Program, an online portal that helps patients navigate the payment process, learn about adherence and possibly receive eligibility for reduced out-of-pocket costs.
According to the release, Arcutis will continue to offer the Arcutis Cares patient assistance program, providing Zoryve for free to eligible patients who are uninsured or underinsured.
Read more about
Click Here to Manage Email Alerts